Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Phase 2 Completed 45 enrolled Santen Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Timeline

Start: 2009-09
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Spinosad	Small molecule	—	Topical

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Summary

Timeline

Drugs

Indications